New licence allows for ongoing product development and the evaluation of cannabis concentrates in portable vaporizer devices for optimal formulations

Starseed and WeedMD become preferred medical cannabis suppliers to over 51,000 myHSA clients across Canada

WeedMD is pleased to announce that it has been named winner in the large-size business category of London’s Best Places to Work 2020 awards program, presented by London Inc. Magazine.

WeedMD is pleased to announce that its shareholders voted in favour of the resolutions approving; 1) the private placement and exercise of subscription receipts with the LiUNA Pension of Central and Eastern Canada or gross proceeds of $25 million and 2) the board nomination rights and voting covenants with certain shareholders of the Company.

Angelo Tsebelis, currently President of WeedMD, is appointed Chief Executive Officer.

WeedMD is pleased to confirm that a special meeting of shareholders of WeedMD will take place as scheduled on February, 4, 2020 at 10:00 a.m. (EST) at Fogler, Rubinoff LLP, located at TD Centre North Tower, Suite 3000, 77 King Street West, Toronto, Ontario.

Starseed is now the preferred medical cannabis supplier to five LiUNA Locals including London Local 1059’s 4,000 members through their health benefit plan.

WeedMD enhances management team & board of directors, announces new chair.

WeedMD is pleased to report its financial and operating results for the three-months ended September 30, 2019, including net revenue of $6.7 million and gross margin of 29%.

WeedMD’s leading cultivation and processing capabilities to provide consistent, high-quality supply for Starseed’s unique sales platform of captive cannabis-insured medical patients.

WeedMD company financials and corporate update will now be filed on November 29, 2019.

Newly-appointed CX team includes veteran pharma leader Tricia Symmes as General Manager and skilled concentrates leader Logan Marynissen as Director of Extraction.

WeedMD company financials and corporate update will be filed after market on November 28, 2019.

Company completes inaugural outdoor cannabis harvest; CX Industries enters commercial operations; Health Canada grants WeedMD approval to produce extracts, edibles & topicals.

WeedMD is pleased to announce that it has secured a Health Canada licence amendment approval for its purpose-built processing facility in Strathroy, Ontario. The stand-alone, 50,000 sq. ft. custom-built structure, located on WeedMD’s 158-acre Strathroy property, will dry, process and cure all remaining outdoor-cultivated cannabis in 2019 and is built to process and store more than 40 tons of dried cannabis biomass.

Experiential event on Oct. 3rd spotlights Company’s unique outdoor cultivation practices.

WeedMD is pleased to announce that it has closed its previously-announced bought-deal short-form prospectus offering of convertible debenture units at a price of $1,000 per Convertible Debenture Unit for aggregate gross proceeds of $13,115,000, which includes proceeds from the over-allotment option. The Offering was led by Mackie Research Capital Corporation, and included Haywood Securities Inc..

WeedMD is pleased to announce that is has entered into a revised agreement with Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters, including Haywood Securities Inc., to increase the size of the previously announced bought-deal short-form prospectus offering to 12,000 convertible debenture units at a price of $1,000 per Debenture Unit, for aggregate gross proceeds to the Company of $12,000,000.

WeedMD is is pleased to announce that is has entered into an agreement with Mackie Research Capital Corporation as the lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters, including Haywood Securities Inc., pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 10,000 convertible debenture units for gross proceeds to the Company of $10,000,000 at a price of $1,000 per Debenture Unit.

WeedMD is pleased to report its financial and operating results for the three months ended June 30, 2019, including net revenue of $8.0 million and a gross margin of 46%.